Repligen gets fast tracked for spinal muscular atrophy

Waltham, MA-based biotech Repligen has received FDA fast-track designation for its spinal muscular atrophy treatment, RG3039. The drug also received orphan drug status from the EMA. Repligen is preparing for its first Phase I trial of the drug. Repligen release